• 2026考研英語全程班 6班
• 26考研全科上岸規劃營「擇校▪規劃▪備考」
• 北京大學2026考研專業課復習資料「真題▪筆記▪講義▪題庫」

劉振明

理學博士，副研究員

藥物化學，藥物設計

電話 & 傳真: +86-10-82805514

                       +86-10-82802724

聯系郵箱: zmliu@bjmu.edu.cn

學習經歷:

1996-2000         理學學士，北京醫科大學藥學院藥物化學專業

2000-2005         理學博士，北京大學化學與分子工程學院物理化學專業 （導師：來魯華）

任職和工作經歷：

2011年-至今               副研究員，北京大學藥學院

2005年-2011年           講師，北京大學藥學院

2007年-2009年        “重大新藥創制”科技重大專項實施管理辦公室

研究方向與興趣：藥物化學與藥物設計。我們的研究興趣主要是:1)發展新的藥物設計方法，并將其應用于藥物的發現過程。2)通過設計和結構修飾生物活性分子針對特定的藥物靶標尋求找到新的具有應用價值的活性先導化合物。

代表性論文和專著：

1. Liu ZM, Li B, Li X, Zhang L, Lai L. Identification of Small-Molecule Inhibitors against Human Leukocyte Antigen-Death Receptor 4 (HLA-DR4) through a Comprehensive Strategy. J Chem. Inf. Model. 2011, 51: 326-334.

2. Fan D, Liu ZM*, Jin HW, Zhang LR. Classification of Coenzyme a Binding Proteins Based on Co-Factor Binding Modes. Acta Phys Chim Sin. 2011.

3. Tian R, Liu ZM*, Jin HW, Zhang LR, Lin WH. Target Identification of Isomalabaricane Terpenes Extracted from Sponges. Acta Phys Chim Sin. 2011.

4. Zheng Z, Liu ZM*. Application of the HSAB Principle for the Quantitative Analysis of Nucleophilicity/Basicity of Organic Compounds with Lone Pair Electrons. J. Chin Pharmaceu Sci. 2011, 20: 125-132.

5. Bo Li, Zhenming Liu*, Liangren Zhang and Lihe Zhang. Multiple-Docking and Affinity Fingerprint Methods for Protein Classification and Inhibitors Selection. J Chem Inf. Comput. Sci. 2009, 50: 1589-1601.

6. Zheng Z, Liu ZM*, Zhang LR. Combined Method for Determining Reaction Transition State Geometry and Energy. Acta Phys Chim Sin. 2009, 25: 1439-1442.

7. Liu ZM*, Huang CK, Fan KQ, Wei P, Chen H, Liu SY, Pei JF, Shi L, Li B, Yang K, Liu Y, Lai LH. Virtual Screening of Novel Noncovalent Inhibitors for SARS-Cov 3C-Like Proteinase. J Chem Inf. Comput. Sci. 2005, 45: 10-17.

8. Liu ZM*†, Li B and Lai LH. Functional Classification of Phospholipase A2 Family. Acta Phys Chim. Sin. 2005, 21: 1143-1145.\

9. Kang LG, Zhang XT, Xie Y, Tu YP, Wang D, Liu ZM, Wang ZY. Involvement of estrogen receptor variant ER-Alpha 36, Not GPR30, in nongenomic estrogen signaling. Mol Endocrinol. 2010, 24: 709-721.

10. Ke YR, Jin HW, Liu ZM, Zhang LR. Homology modeling and structure validation of the Adenosine A(1) receptor. Acta Phys Chim. Sin. 2010, 26: 2833-2839.

11. Zhu YQ , Zhu XR, Wu G, Ma YH, Li YJ,Zhao X, Yuan YX, Yang J, Yu S, Shao F, Li RT, Ke YR, Lu AJ, Liu ZM, Zhang LG. Synthesis, in vitro and in vivo biological evaluation, docking studies, and structure-activity relationship (SAR) discussion of dipeptidyl boronic acid proteasome inhibitors composed of beta-amino acids. J. Med. Chem. 2010, 53: 1990-1999.

12. Zhang SW, Shi YW, Jin HW, Liu ZM, Zhang LR, Zhang LH. Covalent complexes of proteasome model with peptide aldehyde inhibitors MG132 and MG101: docking and molecular dynamics study. J. Mol. Model. 2009, 15: 1481-1490.

13. Han D, Meng XB, Wang LN, Liu H, Yao Y, Wang Z, Yang ZJ, Liu ZM, Li ZJ. Efficient synthesis of a series of novel fructose-based 3-acetyl-5-alkyl-2, 3-dihydro-1,3,4-oxadiazole derivatives and studies of the reaction mechanism. Tetrahedron-Asymmetry. 2009, 20: 399-410.

14. Zhang ZL, Wu J, Ran FX, Guo Y, Tian R, Zhou SX, Wang XW, Liu ZM, Zhang LR, Cui JR, Liu JY. Novel 8-deaza-5,6,7,8-tetrahydroaminopterin derivatives as dihydrofolate inhibitor: Design, synthesis and antifolate activity. European J. Med. Chem. 2009, 44: 764-771.

15. Wang YM, Hu LX, Liu ZM, You XF, Zhang SH, Qu JR, Li ZR, Li Y, Kong WJ, He HW, Shao RG, Zhang LR, Peng ZG, Boykin DW, Jiang JD.   N-(2,6-Dimethoxypyridine-3-Yl)-9-methyl -carbazole-3-sulfonamide as a novel tubulin ligand against human cancer. Clin Cancer Res. 2008, 14: 6218-6227.

16. Lu X, Chen YL, Guo Y, Liu ZM, Shi YW, Xu Y, Wang XW, Zhang ZL, Liu JY. The design and synthesis of N-1-alkylated-5-aminoaryalkylsubstituted-6-methyluracils as potential non-nucleoside HIV-1 RT inhibitors. Bioorg Med Chem Lett. 2007, 15: 7399-407.

17. Shi YW, Liu ZM, Jin HW, Zhang LR, Zhang LH. Quantitative structure-activity relationships of HIV-1 integrase inhibitors of dkas. Acta Phys Chim. Sin. 2007, 23: 1393-1398.

18. Tian R, Ji YB, Liu ZM, Jin HW, Zhang LR, Lin WH. QSAR and binding mode study of a series of combretastatin analogues as tubulin inhibitors. Chem J. Chinese U. 2007, 28: 2150-2155.

19. Liu Y, Zheng TF, Jin F, Zhou L, Liu ZM, Wei P, Lai LH. Design and bioassay of non-peptidic inhibitors of SARS coronavirus 3C-like Proteinase. Acta Chimica Sinica. 2007, 65: 1707-1712.

20. Lv W, Liu ZM, Jin HW, Yu XH, Zhang LR, Zhang LH. Three-Dimensional structure of HIV-1VIF constructed by comparative modeling and the function characterization analyzed by molecular dynamics simulation. Org Biomol Chem. 2007, 5: 617-626.

21. Liu P, Guo HZ, Wang WX, Zhang J, Li N, Han J, Zhou JP, Hu YC, Zhang T, Liu ZM, Guo D. Cytotoxic diterpenoids from the bark of Pseudolarix kaempferi and their structure-activity relationships. J. Nat Prod. 2007, 70: 533-537.

22. Pei JF, Wang Q, Liu ZM, Li Q, Yang K, Lai LH. PSI-DOCK: Towards highly efficient and accurate flexible ligand docking. Proteins. 2006 62(4): 934-946.

23. Zhu YQ, Pei JF, Liu ZM, Lai LH, Cui JR, Li RT. 3D-QSAR studies on tripeptide aldehyde inhibitors of proteasome using comfa and comsia methods. Bioorg Med Chem Lett. 2006, 14: 1483-1496.

24.  Lai LH, Han XF, Chen H, Wei P, Huang CK, Liu SY, Fan KQ, Zhou L, Liu ZM, Pei JF, Liu Y. Quaternary structure, substrate selectivity and inhibitor design for SARS 3C-like proteinase. Curr Pharm Design. 2006, 12: 4555-4564.

25. Pei JF, Chen H, Liu ZM, Han XF, Wang Q, Shen B, Zhou JJ, Lai LH. Improving the quality of 3D-QSAR by using flexible-ligand receptor models. J Chem Inf. Model. 2005, 45: 1920-1933.

26. Huang CK, Gao Y, Liu ZM, Liu Y, Lai LH. Comparative molecular field analysis of pyrrolidine inhibitors for human cytosolic phospholipase A2. Acta Phys-Chim Sin. 2003, 19: 79-81.